158 related articles for article (PubMed ID: 38385070)
21. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.
Konstantinopoulos PA; Spentzos D; Fountzilas E; Francoeur N; Sanisetty S; Grammatikos AP; Hecht JL; Cannistra SA
Cancer Res; 2011 Aug; 71(15):5081-9. PubMed ID: 21676886
[TBL] [Abstract][Full Text] [Related]
22. Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer.
Kaltofen T; Preinfalk V; Schwertler S; Fraungruber P; Heidegger H; Vilsmaier T; Vattai A; Czogalla B; Mayr D; Mahner S; Jeschke U; Trillsch F
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2559-2574. PubMed ID: 32681294
[TBL] [Abstract][Full Text] [Related]
23. ZSWIM4 inhibition improves chemosensitivity in epithelial ovarian cancer cells by suppressing intracellular glycine biosynthesis.
Gong K; Huang Y; Zheng Y; Hao W; Shi K
J Transl Med; 2024 Feb; 22(1):192. PubMed ID: 38383406
[TBL] [Abstract][Full Text] [Related]
24. Galectin-3 regulates chemotherapy sensitivity in epithelial ovarian carcinoma via regulating mitochondrial function.
Wang D; You D; Li L
J Toxicol Sci; 2019; 44(1):47-56. PubMed ID: 30626779
[TBL] [Abstract][Full Text] [Related]
25. Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy.
Hlaváč V; Holý P; Václavíková R; Rob L; Hruda M; Mrhalová M; Černaj P; Bouda J; Souček P
Life Sci Alliance; 2022 Oct; 5(12):. PubMed ID: 36229065
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
Zeng S; Liu S; Feng J; Gao J; Xue F
Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
[TBL] [Abstract][Full Text] [Related]
27. WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response.
Janczar S; Nautiyal J; Xiao Y; Curry E; Sun M; Zanini E; Paige AJ; Gabra H
Cell Death Dis; 2017 Jul; 8(7):e2955. PubMed ID: 28749468
[TBL] [Abstract][Full Text] [Related]
28. The downregulation of miR-509-3p expression by collagen type XI alpha 1-regulated hypermethylation facilitates cancer progression and chemoresistance via the DNA methyltransferase 1/Small ubiquitin-like modifier-3 axis in ovarian cancer cells.
Wu YH; Huang YF; Wu PY; Chang TH; Huang SC; Chou CY
J Ovarian Res; 2023 Jun; 16(1):124. PubMed ID: 37386587
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer.
Guan L; Li Z; Xie F; Pang Y; Zhang C; Tang H; Zhang H; Chen C; Zhan Y; Zhao T; Jiang H; Jia X; Wang Y; Lu Y
J Exp Clin Cancer Res; 2020 Mar; 39(1):53. PubMed ID: 32293499
[TBL] [Abstract][Full Text] [Related]
30. KCNMA1-AS1 attenuates apoptosis of epithelial ovarian cancer cells and serves as a risk factor for poor prognosis of epithelial ovarian cancer.
Ma SY; Wei P; Qu F
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4629-4641. PubMed ID: 31210304
[TBL] [Abstract][Full Text] [Related]
31. CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation.
Dall'Acqua A; Sonego M; Pellizzari I; Pellarin I; Canzonieri V; D'Andrea S; Benevol S; Sorio R; Giorda G; Califano D; Bagnoli M; Militello L; Mezzanzanica D; Chiappetta G; Armenia J; Belletti B; Schiappacassi M; Baldassarre G
EMBO Mol Med; 2017 Oct; 9(10):1415-1433. PubMed ID: 28778953
[TBL] [Abstract][Full Text] [Related]
32. Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing.
Zhao Q; Qian Q; Cao D; Yang J; Gui T; Shen K
J Ovarian Res; 2018 Apr; 11(1):31. PubMed ID: 29685168
[TBL] [Abstract][Full Text] [Related]
33. Exosomes as mediators of platinum resistance in ovarian cancer.
Crow J; Atay S; Banskota S; Artale B; Schmitt S; Godwin AK
Oncotarget; 2017 Feb; 8(7):11917-11936. PubMed ID: 28060758
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer.
Mariya T; Hirohashi Y; Torigoe T; Asano T; Kuroda T; Yasuda K; Mizuuchi M; Sonoda T; Saito T; Sato N
Cancer Immunol Res; 2014 Dec; 2(12):1220-9. PubMed ID: 25324403
[TBL] [Abstract][Full Text] [Related]
35. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB
Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083
[TBL] [Abstract][Full Text] [Related]
36. Endoplasmic Reticulum Stress-Related Ten-Biomarker Risk Classifier for Survival Evaluation in Epithelial Ovarian Cancer and
Zhang M; Wang Y; Xu S; Huang S; Wu M; Chen G; Wang Y
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762313
[TBL] [Abstract][Full Text] [Related]
37. Periostin Secreted by Carcinoma-Associated Fibroblasts Promotes Ovarian Cancer Cell Platinum Resistance Through the PI3K/Akt Signaling Pathway.
Chu L; Wang F; Zhang W; Li HF; Xu J; Tong XW
Technol Cancer Res Treat; 2020; 19():1533033820977535. PubMed ID: 33302812
[TBL] [Abstract][Full Text] [Related]
38. SERPINB3 in the chicken model of ovarian cancer: a prognostic factor for platinum resistance and survival in patients with epithelial ovarian cancer.
Lim W; Kim HS; Jeong W; Ahn SE; Kim J; Kim YB; Kim MA; Kim MK; Chung HH; Song YS; Bazer FW; Han JY; Song G
PLoS One; 2012; 7(11):e49869. PubMed ID: 23185467
[TBL] [Abstract][Full Text] [Related]
39. miR-211 facilitates platinum chemosensitivity by blocking the DNA damage response (DDR) in ovarian cancer.
Wang T; Hao D; Yang S; Ma J; Yang W; Zhu Y; Weng M; An X; Wang X; Li Y; Wu D; Tang J; Yang C; He Y; Zhang L; Jin X; Wang G; Li Z; Zheng T; Meng H; Feng Y; Li X
Cell Death Dis; 2019 Jun; 10(7):495. PubMed ID: 31235732
[TBL] [Abstract][Full Text] [Related]
40. CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
Oyama Y; Shigeta S; Tokunaga H; Tsuji K; Ishibashi M; Shibuya Y; Shimada M; Yasuda J; Yaegashi N
PLoS One; 2021; 16(6):e0251079. PubMed ID: 34161330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
